Point Therapeutics to Present at Upcoming Conferences in New York City

  
    
  
  
    
      Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert, 
      President and CEO, will present at the Rodman & Renshaw 8th Annual 
      Healthcare Conference on Tuesday, November 7, 2006 at 9:30 a.m. Eastern 
      Time and at the CIBC World Markets 17th Annual 
      Healthcare Conference on Wednesday, November 8, 2006 at 11:30 a.m. 
      Eastern Time. Mr. Kiepert will review key research and development 
      accomplishments and discuss ongoing corporate initiatives. The Rodman 
      and Renshaw Conference will be held at the New York Palace Hotel, and 
      the CIBC conference will be held at the Waldorf-Astoria. Live Webcasts 
      of the presentations will be available on the Company's Web site, www.pther.com, 
      and will be archived for 90 days.
    
    
      About Point Therapeutics, Inc.:
    
    
      Point is a Boston-based biopharmaceutical company developing a portfolio 
      of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 
      diabetes and as vaccine adjuvants. Point is currently studying its lead 
      product candidate, talabostat, in two Phase 3 trials in non-small cell 
      lung cancer. Point is also studying talabostat in several Phase 2 
      trials, including as a single-agent in metastatic melanoma, in 
      combination with cisplatin in metastatic melanoma, in combination with 
      rituximab in advanced chronic lymphocytic leukemia, and in combination 
      with gemcitabine in metastatic pancreatic cancer.
    
  
Point Therapeutics, Inc. (NASDAQ:POTP) announced that Don Kiepert,
President and CEO, will present at the Rodman & Renshaw 8th Annual
Healthcare Conference on Tuesday, November 7, 2006 at 9:30 a.m.
Eastern Time and at the CIBC World Markets 17th Annual Healthcare
Conference on Wednesday, November 8, 2006 at 11:30 a.m. Eastern Time.
Mr. Kiepert will review key research and development accomplishments
and discuss ongoing corporate initiatives. The Rodman and Renshaw
Conference will be held at the New York Palace Hotel, and the CIBC
conference will be held at the Waldorf-Astoria. Live Webcasts of the
presentations will be available on the Company's Web site,
www.pther.com, and will be archived for 90 days.

   About Point Therapeutics, Inc.:

   Point is a Boston-based biopharmaceutical company developing a
portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer,
type 2 diabetes and as vaccine adjuvants. Point is currently studying
its lead product candidate, talabostat, in two Phase 3 trials in
non-small cell lung cancer. Point is also studying talabostat in
several Phase 2 trials, including as a single-agent in metastatic
melanoma, in combination with cisplatin in metastatic melanoma, in
combination with rituximab in advanced chronic lymphocytic leukemia,
and in combination with gemcitabine in metastatic pancreatic cancer.